全文获取类型
收费全文 | 9095篇 |
免费 | 726篇 |
国内免费 | 88篇 |
专业分类
耳鼻咽喉 | 81篇 |
儿科学 | 146篇 |
妇产科学 | 116篇 |
基础医学 | 475篇 |
口腔科学 | 461篇 |
临床医学 | 1084篇 |
内科学 | 1150篇 |
皮肤病学 | 55篇 |
神经病学 | 286篇 |
特种医学 | 293篇 |
外科学 | 2237篇 |
综合类 | 1043篇 |
一般理论 | 5篇 |
预防医学 | 1353篇 |
眼科学 | 71篇 |
药学 | 683篇 |
7篇 | |
中国医学 | 68篇 |
肿瘤学 | 295篇 |
出版年
2023年 | 277篇 |
2022年 | 321篇 |
2021年 | 467篇 |
2020年 | 514篇 |
2019年 | 499篇 |
2018年 | 462篇 |
2017年 | 367篇 |
2016年 | 340篇 |
2015年 | 402篇 |
2014年 | 752篇 |
2013年 | 773篇 |
2012年 | 538篇 |
2011年 | 543篇 |
2010年 | 413篇 |
2009年 | 410篇 |
2008年 | 385篇 |
2007年 | 332篇 |
2006年 | 303篇 |
2005年 | 239篇 |
2004年 | 262篇 |
2003年 | 192篇 |
2002年 | 146篇 |
2001年 | 123篇 |
2000年 | 98篇 |
1999年 | 99篇 |
1998年 | 79篇 |
1997年 | 70篇 |
1996年 | 50篇 |
1995年 | 56篇 |
1994年 | 53篇 |
1993年 | 22篇 |
1992年 | 26篇 |
1991年 | 11篇 |
1990年 | 11篇 |
1989年 | 21篇 |
1988年 | 23篇 |
1987年 | 13篇 |
1986年 | 12篇 |
1985年 | 25篇 |
1984年 | 21篇 |
1983年 | 17篇 |
1982年 | 20篇 |
1981年 | 21篇 |
1980年 | 13篇 |
1979年 | 18篇 |
1978年 | 12篇 |
1977年 | 11篇 |
1976年 | 15篇 |
1975年 | 14篇 |
1974年 | 5篇 |
排序方式: 共有9909条查询结果,搜索用时 15 毫秒
1.
2.
3.
《Journal of vascular and interventional radiology : JVIR》2022,33(8):895-902.e4
PurposeTo study, from a U.S. payer’s perspective, the economic consequences of drug-coated balloon (DCB) versus standard percutaneous transluminal angioplasty (PTA) use for the treatment of stenotic lesions in dysfunctional hemodialysis arteriovenous fistulae.Materials and MethodsCost differences between DCBs and PTA at year 1 and beyond were calculated via 2 methods. The first approach used the mean absolute number of trial-observed access circuit reinterventions through 12 months (0.65 ± 1.05 vs 1.05 ± 1.18 events per patient for DCBs and PTA, respectively) and projected treatment outcomes to 3 years. The second approach was based on the trial-observed access circuit primary patency rates at 12 months (53.8% vs 32.4%) and calculated the cost difference on the basis of previously published Medicare cost for patients who maintained or did not maintain primary patency. Assumptions regarding DCB device prices were tested in sensitivity analyses, and the numbers needed to treat were calculated.ResultsUsing the absolute number of access circuit reinterventions approach, the DCB strategy resulted in an estimated per-patient savings of $1,632 at 1 year and $4,263 at 3 years before considering the DCB device cost. The access circuit primary patency approach was associated with a per-patient cost savings of $2,152 at 1 year and $3,894 at 2.5 years of follow-up. At the theoretical DCB device reimbursement of $1,800, savings were $1,680 and $2,049 at 2.5 and 3 years, respectively. The one-year NNT of DCB compared to PTA was 2.48.ConclusionsEndovascular therapy for arteriovenous access stenosis with the IN.PACT AV DCB can be expected to be cost-saving if longer follow-up data confirm its clinical effectiveness. 相似文献
4.
5.
6.
【目的】 以J-Stage平台的概况和日本科技期刊的语种分类为基础,深入分析J-Stage的实施细节及其在推动日本科技期刊发展中的关键作用与角色,对我国期刊发展形成启示。【方法】 采用前瞻研究法,从平台架构、组织和功能方面分析J-Stage的发展现状,并结合日本科技期刊的语种分类进行分析。【结果】 J-Stage的特色在于整合全国学术期刊资源、采取公益性运行机制、重视用户体验、不断更新服务、对接国际标准等,对我国期刊平台建设具有一定的借鉴意义。【结论】 J-Stage的建设有利于日本多语种科技期刊的共同发展和国际影响力提升。国家级科技期刊平台不仅是期刊发展的基础设施,还要兼具前瞻性导向作用和精益管理能力。 相似文献
7.
8.
9.
《Seminars in Arthroplasty》2022,32(4):681-687
BackgroundThe objective of this study was to compare complication rates between patients undergoing reverse shoulder arthroplasty (RSA) after a prior open reduction and internal fixation (ORIF) for proximal humerus fracture (PHF) to those undergoing RSA as a primary treatment for PHFs, glenohumeral osteoarthritis, or rotator cuff tear arthropathy (CTA).MethodsPatients who underwent RSA between 2015 and 2020 were identified in the Mariner database. Patients were separated into 3 mutually exclusive groups: (1) RSA for osteoarthritis, rotator cuff tear, or CTA (Control-RSA); (2) RSA as a primary treatment for PHF (PHF-RSA); and (3) RSA for patients with prior ORIF of PHFs (ORIF-RSA). Ninety-day medical and 2-year postoperative surgical complications were identified. In addition, patients in the PHF-RSA group were subdivided into those undergoing RSA for PHF within 3 months of the fracture (acute) vs. those treated greater than 3 months from diagnosis (delayed). Multivariate regression was performed to control for differences in comorbidities and demographics.ResultsA total of 30,824 patients underwent primary RSA for arthritis or CTA, 5389 patients underwent RSA as a primary treatment for a PHF, and 361 patients underwent RSA after ORIF of a PHF. ORIF before RSA was associated with an increased risk of overall revision (odds ratio [OR] 2.45, P = .002), infection (OR 2.40, P < .001), instability (OR 2.43, P < .001), fracture (OR 3.24, P = .001), minor medical complications (OR 1.59, P = .008), and readmission (OR 2.55, P = .001) compared with the Control-RSA cohort. RSA as a primary treatment for PHF was associated with an increased risk of 2-year revision (OR 1.60, P < .001), infection (OR 1.51, P < .001), instability (OR 2.84, P < .001), and fracture (OR 2.54, P < .001) in addition to major medical complications (OR 2.02, P < .001), minor medical complications (OR 1.92, P < .001), 90-day emergency department visits (OR 1.26, P < .001) and 90-day readmission (OR 2.03, P < .001) compared with the Control-RSA cohort. The ORIF-RSA group had an increased risk of periprosthetic infection (OR 1.94, P = .002) when compared with the PHF-RSA cohort. There were no differences in medical or surgical complications in the RSA-PHF cohort between patients treated in an acute or delayed fashion.ConclusionRSA following ORIF of a PHF is associated with increased complications compared with patients undergoing RSA for nonfracture indications. Prior ORIF of a PHF is also an independent risk factor for postoperative infection after RSA compared with patients who undergo RSA as a primary operation for fracture. The timing of RSA as a primary operation for PHF does not appear to impact the rates of postoperative medical and surgical complications. 相似文献
10.